01/27/2012 A large, multicenter study shows that women with ovarian cancer who have mutations in the BRCA1 or BRCA2 genes have better survival rates than women who do not have such mutations… Read on
Recent studies have shown that women with ovarian cancers that result from an inherited mutation in the BRCA gene, show an excellent response to a drug called a PARP inhibitor… Read on
Mutations in the BRCA1 gene account for more than 30 percent of hereditary ovarian cancer and loss of BRCA1 expression has been shown in 30 percent to 60 percent of sporadic [or non-hereditary] ovarian cancers, the more common types of ovarian… Read on
In some families, ovarian cancer is caused by the inaction of the tumor-suppressor gene, BRCA1. Dr. El Shamy has has discovered a second protein produced at the BRCA1 gene location, named IRIS, the function of which is not known. But Dr… Read on
A recent study published in Nature Cancer talks about harnessing the power of machine learning to help predict prognosis and response to treatment for those with high-grade serous ovarian cancer (HGSOC)… Read on
Submitted by ovarian cancer survivor Annie Ellis, OCRA Research Advocate and Scientific Advisory Committee member This year’s SGO annual meeting was held in Phoenix, Arizona from March 18-21… Read on
Cervical cell samples that are routinely collected as part of Pap smears may hold promise for predicting the risk of ovarian and other cancers, according to recent findings published as two separate papers in Nature — one focused on… Read on
Over the past decade, a new class of drugs called PARP inhibitors have been approved by the Food and Drug Administration (FDA) for use in ovarian cancer… Read on
New study findings not only reveal where the most common ovarian cancer subtype originates in certain patients, but also point to the future possibility of being able to predict who will get the disease… Read on
Hereditary breast and ovarian cancer syndrome, known as HBOC, refers to a predisposition to develop cancer that is passed down through the generations of a family. HBOC is inherited in the form of a harmful mutation, or change, in a gene… Read on
Dr. Thales Nepomuceno obtained his B.Sc. degree in biology at the Federal Institute of Rio de Janeiro (Brazil) in 2014. He also holds an M.Sc. (2016) and a Ph.D. (2020) degree in Oncology from the Brazilian National Cancer Institute… Read on
More breakthroughs are on the horizon, as OCRA has awarded grants to 22 dedicated scientists at 15 prestigious medical institutions to enable future ovarian cancer discoveries… Read on
